IDH1 and IDH2 Driven Intrahepatic Cholangiocarcinoma (IHCC): A comprehensive genomic and immune profiling study.

被引：8
|
作者：
Makawita, Shalini
Borad, Mitesh J.
Carapeto, Fernando
Kwong, Lawrence
Bekaii-Saab, Tanios S.
Murugesan, Karthikeyan
Ross, Jeffrey S.
Danziger, Natalie
Israel, Mason A.
McGregor, Kimberly
Janku, Filip
Javle, Milind M.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Mayo Clin, Scottsdale, AZ USA
[3] Mayo Clin, Div Hematol Oncol, Phoenix, AZ USA
[4] Fdn Med Inc, Cambridge, MA USA
[5] Fdn Med, Cambridge, MA USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.4009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4009
引用
收藏
页数：3
相关论文
共 50 条
  • [31] IDH1 and IDH2 mutations in pediatric acute leukemia
    A K Andersson
    D W Miller
    J A Lynch
    A S Lemoff
    Z Cai
    S B Pounds
    I Radtke
    B Yan
    J D Schuetz
    J E Rubnitz
    R C Ribeiro
    S C Raimondi
    J Zhang
    C G Mullighan
    S A Shurtleff
    B A Schulman
    J R Downing
    Leukemia, 2011, 25 : 1570 - 1577
  • [32] IDH1 and IDH2 mutations in pediatric acute leukemia
    Andersson, A. K.
    Miller, D. W.
    Lynch, J. A.
    Lemoff, A. S.
    Cai, Z.
    Pounds, S. B.
    Radtke, I.
    Yan, B.
    Schuetz, J. D.
    Rubnitz, J. E.
    Ribeiro, R. C.
    Raimondi, S. C.
    Zhang, J.
    Mullighan, C. G.
    Shurtleff, S. A.
    Schulman, B. A.
    Downing, J. R.
    LEUKEMIA, 2011, 25 (10) : 1570 - 1577
  • [33] Mutations of IDH1 and IDH2 are not frequent in Multiple Myeloma
    Langer, C.
    Ibanez, M.
    Liebisch, P.
    Zenz, T.
    Knop, S.
    Einsele, H.
    Paschka, P.
    Doehner, H.
    Doehner, K.
    ONKOLOGIE, 2011, 34 : 159 - 159
  • [34] IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
    Cerchione, Claudio
    Romano, Alessandra
    Daver, Naval
    DiNardo, Courtney
    Jabbour, Elias Joseph
    Konopleva, Marina
    Ravandi-Kashani, Farhad
    Kadia, Tapan
    Martelli, Maria Paola
    Isidori, Alessandro
    Martinelli, Giovanni
    Kantarjian, Hagop
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [35] Evaluation of Efficiency-Driven Adjustments to the Abbott RealTime IDH1 and IDH2 Assays
    Carlin, A. M.
    Sondermann, J.
    Herlihy, S. E.
    Van Deerlin, V. M.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2019, 21 (06): : 1142 - 1142
  • [36] Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia
    Ragon, Brittany Knick
    DiNardo, Courtney D.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2017, 12 (06) : 537 - 546
  • [37] IDH1 and IDH2 : Founding or Progressor Mutations in Myeloid Neoplasms
    Ma, Wanlong
    De Dios, Ivan
    Funari, Vincent
    Sudarsanam, Sucha
    Jiang, Shi-Ping
    Agersborg, Sally
    Hummel, Jennifer
    Blocker, Forrest
    Albitar, Maher
    BLOOD, 2017, 130
  • [38] Comparing the Oncogenic Effects of IDH1 and IDH2 Mutations in Chondrosarcoma
    Phillips, Jenny
    Stacey, Michael
    Osgood, Christopher
    IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 2023, 59 : S106 - S107
  • [39] FDA approves IDH1 and IDH2 inhibitor for brain cancer
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (10) : 731 - 731
  • [40] IDH1 and IDH2 mutations are rare in pediatric myeloid malignancies
    K Oki
    J Takita
    M Hiwatari
    R Nishimura
    M Sanada
    J Okubo
    M Adachi
    M Sotomatsu
    A Kikuchi
    T Igarashi
    Y Hayashi
    S Ogawa
    Leukemia, 2011, 25 : 382 - 384
12345